NAFLD, NASH and liver cancer

Area of Science:

• Hepatology
• Oncology
• Metabolic Syndrome Research

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a growing global epidemic.
• NAFLD is a significant risk factor for liver cancer, particularly hepatocellular carcinoma (HCC), which has poor outcomes.
• The incidence of HCC and intrahepatic cholangiocarcinoma is rising, with HCC being a leading cause of obesity-related cancer deaths in US men.

Purpose of the Study:

• To review the association between NAFLD-related cirrhosis and liver cancer.
• To explore the role of metabolic syndrome in liver cancer development across various etiologies.
• To discuss recent advances in understanding NAFLD progression to HCC from preclinical models.

Main Methods:

• Literature review summarizing correlations between NAFLD and liver cancer.
• Discussion of preclinical models elucidating NAFLD to HCC progression pathways.
• Analysis of targeted genetic manipulations in metabolic and stress-response pathways.

Main Results:

• NAFLD and metabolic syndrome are implicated in the development of diverse liver cancers.
• Genetic manipulation studies have identified key pathways (e.g., one-carbon metabolism, NF-κB, PTEN, microRNAs) regulating NAFLD carcinogenesis.
• Significant advances have been made in identifying diagnostic and therapeutic opportunities.

Conclusions:

• While progress has been made, substantial knowledge gaps remain regarding the precise mechanisms by which NAFLD and its risk factors drive liver cancer.
• Further research is needed to fully elucidate these complex pathways for improved patient outcomes.